Guggenheim upgrades Zscaler stock rating to buy on valuation By Investing.com

Guggenheim upgraded Zscaler to Buy and set a $214 price target, implying 53% upside, after the stock fell about 24% following its Q3 earnings report. The firm said Zscaler de-risked revenue and ARR guidance, though management’s early FY2027 outlook came in below Street expectations and reflected go-to-market turnover plus Red Canary renewal dynamics. Shares remain down 42.6% over six months despite analyst revisions and a consensus Buy rating.

Analysis

CoreWeave’s early deployment of Vera Rubin is less about a single customer win and more about signaling that the next GPU cycle is already moving from “announced” to “installed.” That tends to pull demand forward across the whole AI infrastructure stack: hyperscaler and neocloud capex, networking, power, and liquid cooling vendors all get a second-order bid when the market believes a new architecture can be monetized immediately rather than after a long qualification period. The near-term winner is NVDA through narrative reinforcement, but the real economic benefit accrues to vendors with supply priority and design wins on the deployment path.

For Zscaler, the setup looks like a classic post-earnings positioning reset rather than a broken thesis. The key question is whether the guidance disappointment is a one-quarter air pocket caused by sales force turnover and renewals, or a more persistent deceleration in new-logo conversion. If it’s the former, the stock can rebound quickly because the valuation has already compressed to a level where modest reacceleration can drive multiple expansion; if it’s the latter, the downside is likely to come from estimate cuts over the next 1-2 reporting cycles, not an immediate collapse. The market seems to be pricing execution risk more than structural demand erosion.

The contrarian view is that the selloff in Zscaler may have overshot the actual earnings power reset, especially if ARR guidance simply lags revenue by a quarter or two. Conversely, the AI infrastructure trade may be getting more crowded exactly as the market starts to extrapolate the Rubin cycle too aggressively; the risk is that component bottlenecks, power constraints, or customer digestion turn a perceived acceleration into a staggered rollout. In other words, NVDA remains the cleanest expression, but the higher-beta beneficiaries could underperform if the installation curve proves less linear than the headline suggests.

Key Decisions for Investors

• Long NVDA on any weakness over the next 1-2 sessions; use the CoreWeave deployment as a catalyst for a 3-6 month multiple extension trade, with downside limited by already-high strategic demand visibility.
• Buy CRWV on pullbacks as a high-beta AI infrastructure proxy; pair against a short basket of slower-moving software names to isolate capex acceleration, but size modestly given execution and financing risk.
• Initiate a tactical long ZS only after the next management commentary confirms no additional sales disruption; target a 2-3 month mean reversion trade with upside to prior valuation bands, but keep a tight stop if ARR estimates continue to fall.
• If already long ZS, hedge with near-dated puts into the next earnings cycle; the risk/reward is skewed to estimate revisions over the next 30-60 days, while the upside likely needs a clean guide-up to re-rate.
• Watch FTNT as a relative-beneficiary/relative-seller pair versus ZS: if concern shifts from category demand to execution, FTNT should hold up better on a 1-2 quarter horizon.